UNSPSC 51411501: Burodiline

This classification denotes a vasodilating agent with the molecular formula C19H29NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4006BCR8NJ, chemically known as 2-(1-pyrrolidinyl)ethyl 4-butoxy-3,5-dimethoxybenzoat but generally known as burodiline, which bears US NIH Compound Identifier 189887. European Medicines Agency schedules Burodiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05990MIG. The term BURODILINE is an International Non-Proprietary Name.

UNSPSC 51411501 Burodiline (Commodity) encompasses prescription and over-the-counter pharmaceutical products that state and local governments procure for emergency medical services, health and human services agencies, and institutional healthcare settings. Recent solicitations show state and local buyers purchasing specific emergency medications (epinephrine, labetalol, adenosine, diltiazem), generic multi-source pharmaceuticals distributed through wholesalers, and direct-to-manufacturer prescription programs. Issuing bodies span municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances. The City of Tampa Fire Rescue, Texas Health and Human Services Commission, and Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the range of end users, from single-jurisdiction emergency services to regional and statewide procurement consortia serving multiple jurisdictions and institutions.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) on April 24, 2026, for Advanced Life Support Medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials with nine-month minimum shelf life and firm, one-year contract terms with renewal options. The Minnesota Department of Administration's Office of State Procurement issued an RFP (S1070000015802) through MMCAP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with a March 26, 2026, response deadline and July 1, 2026, effective date. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription capabilities without traditional pharmacy benefit manager or group purchasing organization intermediaries. All three solicitations require FDA compliance, Safety Data Sheets or manufacturing certifications, and demonstrated wholesale or direct-distribution relationships.